NCT04304690: SEROCOV

COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic

Completed NA Last updated 6 July 2022

What this trial tests

NA trial testing blood sample in Sars-CoV2 in 1,177 participants. Completed in 7 July 2021.

Timeline

16 March 2020

Primary endpoint
7 July 2021

7 July 2021

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	1,177
Start date	16 March 2020
Primary completion	7 July 2021
Estimated completion	7 July 2021
Sites	1 location across France

Drugs / interventions tested

• blood sample — full drug profile →

Conditions studied

• Sars-CoV2 — all drugs for Sars-CoV2 →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Eligibility, any sex, with Sars-CoV2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The epidemic due to the Sars-CoV2 virus is spreading in France, without knowning precisely since when the virus has actually circulated on the territory. Data from China but also systematic samples taken from the passengers of the Diamond Princess boat also report almost 50% of asymptomatic forms of Covid-19. The medical and paramedical staff of the front-line services for the care of patients infected with Covid-19 are in fact potentially exposed to the risk of occupational contamination due to the large number of patients treated, including in the pre-epidemic phase. Therefore, and despite the application of standard protective measures, it is possible that a certain number of these personnel already have or will contract Covid-19 disease, including in its asymptomatic form.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Antibody tests for identification of current and past infection with SARS-CoV-2.
   Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, et al · · 2020 · cited 617× · PMID 32584464 · DOI 10.1002/14651858.cd013652
2. COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease.
   Sheervalilou R, Shirvaliloo M, Dadashzadeh N, Shirvalilou S, et al · · 2020 · cited 45× · PMID 32452539 · DOI 10.1002/jcp.29735
3. Long-term evolution of humoral immune response after SARS-CoV-2 infection.
   Teyssou E, Zafilaza K, Sayon S, Marot S, et al · · 2022 · cited 6× · PMID 35307573 · DOI 10.1016/j.cmi.2022.03.012
4. Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris: the SEROCOV cohort study.
   Hausfater P, Boutolleau D, Lacombe K, Beurton A, et al · · 2022 · cited 5× · PMID 35508515 · DOI 10.1038/s41598-022-10945-y
5. Tracheostomy in COVID-19 acute respiratory distress syndrome patients and follow-up: A parisian bicentric retrospective cohort.
   Evrard D, Jurcisin I, Assadi M, Patrier J, et al · · 2021 · cited 5× · PMID 34936655 · DOI 10.1371/journal.pone.0261024
6. Cumulative Incidence of SARS-CoV-2 Infection and Associated Risk Factors Among Frontline Health Care Workers in Paris, France: The SEROCOV Prospective Cohort Study
   Hausfater P, Boutolleau D, Lacombe K, Beurton A, et al · · 2021 · DOI 10.21203/rs.3.rs-960512/v1
7. Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris, France: the SEROCOV prospective cohort study
   Hausfater P, Boutolleau D, Lacombe K, Beurton A, et al · · 2021 · DOI 10.1101/2021.03.09.21253200
8. Cumulative Incidence of SARS-CoV-2 Infection and Associated Risk Factors Among Frontline Health Care Workers in Paris, France: The SEROCOV Prospective Cohort Study
   Hausfater P, Boutolleau D, Lacombe K, Beurton A, et al · · 2021 · DOI 10.2139/ssrn.3781650